Abstract:The complex pathogenesis of atopic eczema involves an impaired epidermal barrier, dysbiosis, and aberrant type 2 immunity (Eyerich and Eyerich, 2018Eyerich K. Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases.J Eur Acad Dermatol Venereol. 2018; 32: 692-703Crossref PubMed Scopus (60) Google Scholar; Werfel et al., 2015Werfel T. Heratizadeh A. Niebuhr M. Kapp A. Roesner L.M. Karch A. et al.Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber.J Allergy Clin Immunol. 2015; 136: 96-103.e9Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar) depending on cytokines such as IL-4, IL-5, IL-9, IL-13, and IL-31 as well as eosinophils, basophils, mast cells, and IgE (Eyerich and Eyerich, 2018Eyerich K. Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases.J Eur Acad Dermatol Venereol. 2018; 32: 692-703Crossref PubMed Scopus (60) Google Scholar). This is underpinned by the clinical efficacy of novel therapeutic targets interacting with type 2 immunity such as the IL-4Ra antibody dupilumab (Blauvelt et al., 2017Blauvelt A. de Bruin-Weller M. Gooderham M. Cather J.C. Weisman J. Pariser D. et al.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 2287-2303Abstract Full Text Full Text PDF PubMed Scopus (551) Google Scholar). The role of IgE in the pathogenesis of atopic eczema is discussed controversially because an intrinsic type of atopic eczema with normal IgE levels exists. However, IgE levels usually correlate well with atopic eczema severity (Aral et al., 2006Aral M. Arican O. Gul M. Sasmaz S. Kocturk S.A. Kastal U. et al.The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis.Mediators Inflamm. 2006; 2006: 73098Crossref PubMed Scopus (43) Google Scholar), and anti-IgE therapies, for example, with omalizumab, a humanized anti-IgE antibody, or selective IgE immune apheresis (IA) are efficient at least in a subgroup of patients. It was shown that cytokine levels in the skin but not circulating IgE correlate with long-term clinical response (Reich et al., 2019Reich K. Hartjen A. Reich J. Schröder J. Steingrube N. Bresch M. et al.Immunoglobulin E-selective immunoadsorption reduces peripheral and skin-bound immunoglobulin E and modulates cutaneous IL-13 expression in severe atopic dermatitis.J Invest Dermatol. 2019; 139: 720-723Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar). However, the underlying mechanisms are still poorly understood. Therefore, the aim of this study was to identify the mode of action of IA and to define the biomarkers predicting therapeutic outcome. Experiments were approved by the Paul Ehrlich Institute and by the ethics committee of the Faculty of Medicine of Technical Uninversity of Munich, and written informed patients’ consent was obtained. A total of 10 patients with highly elevated serum IgE levels (15.032 ± 10.226 IU/ml) were treated with 10 sessions of IA (Figure 1a and Supplementary Table S1), with a follow-up after 4 weeks. Circulating IgE levels were efficiently reduced after each IA session but were fully restored at follow-up in all the patients (Figure 1b). Nevertheless, some patients showed sustained clinical improvements at follow-up. Patients were clustered into responders and non-responders by means of minimum value of the root mean square distance and were defined by scoring atopic dermatitis (SCORAD) 40 responses (Figure 1b and e). Circulating IgE levels tended to correlate with the SCORAD before IA (r = 0.619, P = 0.056) and at follow-up; responders showed a trend for lower IgE levels and a significant reduction of SCORAD (Figure 1c and d). Improvement of life quality, pruritus, colonization of eczematous skin with Staphylococcus aureus emphasized clinical efficacy of IA in responders (Figure 1f), which was also reflected in decreased serum CCL17 levels and cutaneous levels of human β-defensin 2 (Figure 1g). Clustering of patients could not detect a distinct responder endotype regarding cytokine and chemokine levels (Supplementary Figure S1a and b). Apart from the lower CCL17 levels and partially upregulated IFN-γ in responders only on follow-up compared with that on the baseline, no individual mediator indicated clinical response (Supplementary Figure S1b and c). Besides, absolute cell counts of different peripheral immune cells and their relative distribution, their viability, and their stimulatory or proliferative capacity were analyzed to exclude unspecific effects of the IA procedure itself, showing no alterations (Supplementary Figure S2). To confirm a possible role of IgE in the regulation of IgE receptors expression, we investigated the frequencies of cells positive for low-affinity IgE receptor CD23 and high-affinity IgE receptor FcεRI as well as alterations of receptor densities by flow cytometric analysis in the blood. The overall receptor density of both IgE receptors on immune cells showed a tendency to decrease over time in responders but not in non-responders (Figure 2a and Supplementary Figure S3a). FcεRIα expression did not change significantly on B cells, eosinophils, basophils, and monocytes (Supplementary Figure S3b). However, CD23 expression remained at lower levels at follow-up than at baseline on immune cells. This overall decrease of CD23 was also reflected partially on monocytes but more consistently on pan B cells (Figure 2b and c). The effect of CD23 downregulation was most prominent in the CD38highCD24− B-cell population consisting of plasmablasts and plasma cells (Figure 2d). In this study, a remarkable downregulation of CD23 was observed starting at the end of the first cycle after the fourth IA treatment in responders but not in non-responders. For CD23 levels and SCORAD, a parallel course over the treatment time was observed (Supplementary Figure S3d). Moreover, CD23 levels in responders and non-responders showed a trend to correlate with SCORAD at follow-up (Figure 2e). To independently prove the functional relevance of IgE-mediated decrease of CD23 expression on B cells, circulating B cells were isolated at follow-up and stimulated with α-IgE (Figure 2f). The B cells obtained from responders secreted less TNF-α (14.133 ± 9.303 vs. 236.89 ± 183.718 pg/ml, P = 0.4171), IL-6 (53.825 ± 52.174 vs. 1,328.195 ± 847.546 pg/ml, P = 0.2078), and CCL17 (1.477 ± 0.16 vs. 4.95 ± 2.131 pg/ml, P = 0.1794) than those from non-responders (Figure 2g). Further proinflammatory (CXCL8, G-CSF, VEGF) and type 2 immunity (CCL5, IL-5, IL-9) markers were additionally secreted in lower amounts by B cells obtained from the responders (Supplementary Figure S4). Besides, the B cell derived CCL5 (r = 0.755; P = 0.083), IL-5 (r = 0.741; P = 0.092), and IL-9 (r = 0.692; P = 0.128) showed a positive correlation with CD23 expression on B cells (Figure 2h). Of note, CD23 levels on the B cells significantly correlated with serum IgE level (r = 0.892; P = 0.003) and showed positive correlation with serum CCL5 (r = 0.551; P = 0.157) and CCL17 (r = 0.76; P = 0.029), whereas serum IFN-γ correlated negatively (r = −0.595; P = 0.120) (Figure 2i). CD23 plays an important role at the interface of B and T cells by enhancing IgE-mediated antigen uptake, processing, and presentation to T cells (Kehry and Yamashita, 1989Kehry M.R. Yamashita L.C. Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing.Proc Natl Acad Sci USA. 1989; 86: 7556-7560Crossref PubMed Scopus (216) Google Scholar). Besides, CD23 controls the secretion of immune mediators by B cells. In line with this, neutralization of CD23 using the mAb lumiliximab resulted in inhibited antigen-specific lymphocyte proliferation and reduced secretion of proinflammatory cytokines as well as type 2 cytokines such as IL-5 (Poole et al., 2005Poole J.A. Meng J. Reff M. Spellman M.C. Rosenwasser L.J. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects.J Allergy Clin Immunol. 2005; 116: 780-788Abstract Full Text Full Text PDF PubMed Scopus (77) Google Scholar). Correlations of IgE and CD23 expression on B cells have already been described earlier (Czarnowicki et al., 2016Czarnowicki T. Gonzalez J. Bonifacio K.M. Shemer A. Xiangyu P. Kunjravia N. et al.Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis.J Allergy Clin Immunol. 2016; 137: 118-129.e5Abstract Full Text Full Text PDF PubMed Scopus (73) Google Scholar; Selb et al., 2017Selb R. Eckl-Dorna J. Neunkirchner A. Schmetterer K. Marth K. Gamper J. et al.CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells.J Allergy Clin Immunol. 2017; 139: 290-299.e4Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar). Moreover, we showed CD23-dependent TNF-α secretion of B cells as well as the secretion of GM-CSF and IL-6, which was decreased in the responder group. TNF-α induces CCL17 secretion by keratinocytes (Yu et al., 2002Yu B. Koga T. Urabe K. Moroi Y. Maeda S. Yanagihara Y. et al.Differential regulation of thymus- and activation-regulated chemokine induced by IL-4, IL-13, TNF-alpha and IFN-gamma in human keratinocyte and fibroblast.J Dermatol Sci. 2002; 30: 29-36Abstract Full Text Full Text PDF PubMed Scopus (45) Google Scholar), and GM-CSF and IL-6 can trigger CCL17 production in dendritic cells (Achuthan et al., 2016Achuthan A. Cook A.D. Lee M.C. Saleh R. Khiew H.W. Chang M.W. et al.Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation.J Clin Invest. 2016; 126: 3453-3466Crossref PubMed Scopus (69) Google Scholar); diminished secretion of those mediators by B cells from responders might contribute to decreased serum CCL17 level. Several feedback loops control the expression of CD23 on B cells, for example, circulating IgE (Sherr et al., 1989Sherr E. Macy E. Kimata H. Gilly M. Saxon A. Binding the low affinity Fc epsilon R on B cells suppresses ongoing human IgE synthesis.J Immunol. 1989; 142: 481-489PubMed Google Scholar), as well as T cell cytokines. In the latter case, CD23 is induced by type 2 cytokine IL-4 but downregulated by IFN-γ (Prinz et al., 1990Prinz J.C. Baur X. Mazur G. Rieber E.P. Allergen-directed expression of Fc receptors for IgE (CD23) on human T lymphocytes is modulated by interleukin 4 and interferon-gamma.Eur J Immunol. 1990; 20: 1259-1264Crossref PubMed Scopus (40) Google Scholar). Our study certainly has limitations. First, owing to the complex and time-consuming technique of IA with patients spending several hours over several weeks stationary in the clinic, it was not possible to establish a placebo group. Owing to the same reason, the study cohort is rather small. Therefore, wherever possible, findings were validated by measuring different parameters or by performing in vitro approaches. Although these data need to be interpreted carefully regarding these limitations, we think that our study provides interesting evidence for the mode of action as well as for a biomarker of IA, which could be a starting point for further studies. In this study, we show that IA acts through the downregulation of the low-affinity IgE receptor CD23 in a distinct B-cell subset exclusively in clinical responders. This resulted in lower secretion of IL-6, TNF-α and CCL5, cytokines, and chemokines that are involved in type 2 immunity. By means of these findings, we suggest that CD23 is a regulator of long-term type 2 immune responses and can be used as an early biomarker in determining sustained clinical response to IA or possibly type 2‒directed therapies in general. The authors declare that all the data supporting the findings of this study are available within the manuscript or are available from the corresponding authors upon request. Jenny Thomas: http://orcid.org/0000-0002-6386-7352 Rosi Wang: http://orcid.org/0000-0001-5235-516X Richa Batra: http://orcid.org/0000-0003-3708-0086 Alexander Böhner: http://orcid.org/0000-0003-1590-0805 Natalie Garzorz-Stark: http://orcid.org/0000-0002-7409-7883 Bernadette Eberlein: http://orcid.org/0000-0003-4509-6491 Fabian Theis: http://orcid.org/0000-0002-2419-1943 Tilo Biedermann: http://orcid.org/0000-0002-5352-5105 Carsten Schmidt-Weber: http://orcid.org/0000-0002-3203-8084 Alexander Zink: http://orcid.org/0000-0001-9313-6588 Kilian Eyerich: http://orcid.org/0000-0003-0094-2674 Stefanie Eyerich: http://orcid.org/0000-0002-1166-2355 The authors state no conflict of interest. We thank Jana Sänger for excellent technical support. This study was performed with samples of the Biobank Biederstein of the Technical University of Munich (Munich, Germany). This study was supported by a grant of Miltenyi Biotec (Bergisch Gladbach, Germany). Conceptualization: KE, SE, AZ; Data Curation: JT, RW; Formal Analysis: JT, RW, RB, FT; Funding Acquisition: KE, AZ; Investigation: JT, RW; Methodology: JT, KE, SE, AZ; Project Administration: JT, KE, SE, AZ; Resources: KE, SE, AZ, BE, TB, CSW; Software: RB, FT; Supervision: JT, KE, SE, AZ; Validation: JT, RW, KE, SE, NGS, AB; Visualization: JT, RW, KE, SE, NGS; Writing - Original Draft Preparation: JT, RW, KE, SE; Writing - Review and Editing: KE, SE, AZ, BE, TB, CSW A total of 10 patients with atopic eczema were recruited for the study. The diagnosis was based on the criteria of Hanifin and Raijka combined with clinical history, symptoms, and clinical and histologic examination. Individuals with systemic immune-suppressive therapy were excluded from the study. Patient characteristics are summarized in Supplementary Table S1. The study was conducted according to the Helsinki declaration; written informed consent was obtained from every participant before study inclusion, and the study was approved by the local ethical committee (reference number 2486/09). Patients received a total of 10 selective IgE immune apheresis (IA) sessions using TheraSorb-IgE LIFE 18 (Miltenyi Biotec, Bergisch Gladbach, Germany) that were performed in 3 intervals with selective IgE IA on 3 or 4 consecutive days. A follow-up examination was performed 4 weeks after the last treatment. Scoring atopic dermatitis was used to determine the disease severity before every treatment day and at follow-up. The total IgE levels were measured using automated systems (Phadia, Freiburg, Germany) before and after each treatment day and at follow-up. Six-millimeter punch biopsies were obtained under local anesthesia before selective IgE IA and at follow-up and used for histologic analysis and RNA isolation. Staphylococcus aureus colonization was determined by the culture of microbiological swaps before selective IgE IA and at follow-up. Blood basophil, eosinophil, neutrophil, monocyte, and lymphocyte numbers were determined by using an automated hematocytometer (Advia 120 Hematology System, Siemens, Munich, Germany). After lysis of red blood cells, peripheral blood cells were stained with Viobility 405/520 Fixable Dye (Miltenyi Biotec) to exclude dead cells from analysis. After incubation with Human BD Fc Block (Becton, Dickinson and Company, Franklin Lakes, NJ), cells were stained for 30 minutes at 4 °C using fluorochrome-labeled antibodies binding to cell-surface markers: BV421-CD24 (clone ML5), BV605-CD19 (clone SJ25C1), BV650-CD14 (clone M5E2), APC-Cy7-CD16 (clone 3G8), FITC-CD38 (clone HIT1) (all from BD Biosciences, Heidelberg, Germany), PE-FcεRIα (clone CRA1), PE-CD138 (clone 44F9), APC-CD193 (clone 5E8.4), VioBright FITC-CD19 (clone LT19), PE-Vio770-CD23 (clone M-L23.4), APC-CD27 (clone REA499), PE-CD32 (clone 2E1), APC-Vio770-CD3(clone BW264/56), VioBlue-CD3 (clone BW264/56), PE-Vio615-CD56 (clone REA196), and PerCP-Vio700-CD64 (clone REA196) (all from Miltenyi Biotec). Cells were acquired with an LSRFortessa flow cytometer (BD Biosciences) and analyzed using FlowJo software, version 10 (FlowJo, LLC, Ashland, Oregon). Immune cells were differentiated on the basis of the expression of certain surface markers as follows: Basophils (CCR3+SSClow), eosinophils (CCR3+SSChigh), neutrophils (CCR3−SSChigh), monocytes (CD14+), T cells (CD3+), NK T cells (CD3+CD56+), NK cells (CD3−CD56+), and B cells (CD19+). The CD19+ B-cell population was further subdivided into five subsets according to their CD24 and CD38 expression, two markers that are expressed on all B cells but differentially regulated during B-cell development. This well-established approach enables to distinguish CD24+CD38− primarily memory B cells, CD24intCD38int mature naive B cells, CD24highCD38high transitional B cells (also regulatory B cells), CD24−CD38+ plasmablasts (also plasma cells), and CD24−CD38− new memory B cells. All immune cell populations were further analyzed for their IgE receptor expression profile (FceRI and CD23). Basophil activation tests from whole blood were performed by using the Bühlmann Flow CAST assay kit (BÜHLMANN Laboratories AG, Schönenbuch, Switzerland), according to the manufacturer’s instructions. In brief, whole blood was stimulated with anti-FcεRI, fMLP, or left unstimulated as control with parallel staining for surface CCR3 and CD63. After erythrocyte lysis, basophil activation was detected by flow cytometry. PBMCs were isolated by density gradient centrifugation. Briefly, EDTA blood was diluted at 1:2 with PBS (without calcium and magnesium) and carefully layered on lymphoprep solution (Stemcell Technologies, Vancouver, Canada). After a centrifugation step, the PBMC band was collected and washed with PBS (without calcium and magnesium, supplemented with 5 mM EDTA). PBMCs were cultured either in medium (RPMI supplemented with 5% human serum, 2 mmol/l glutamine, 1 mmol/l sodium pyruvate, 1% nonessential amino acids, and 1% penicillin and/or streptomycin) alone or stimulated with plate-bound anti-CD3 and soluble anti-CD28 (both 0.75 μg/ml) mAbs or phytohemagglutinin (1 ng/ml), respectively, for 72 hours at 37 °C and 5% carbon dioxide. B cells were isolated from PBMCs with magnetic beads using a Pan B cell kit (Miltenyi Biotec) yielding an untouched cell population containing all B-cell subpopulations. B cells were cultured either in medium (RPMI supplemented with 5% human serum, 2 mmol/l glutamine, 1 mmol/l sodium pyruvate, 1% nonessential amino acids, and 1% penicillin and/or streptomycin) alone or stimulated with 150 μg/ml α-IgE (Dako, Glostrup, Denmark) for 48 hours at 37 °C and 5% carbon dioxide. Where indicated, B cells were preincubated with 2 μg/ml recombinant IgE (EMD Millipore, Billerica, MA) for 6 hours. After removing supernatant with unbound IgE, spiked B cells were stimulated with 150 μg/ml α-IgE (Dako) for 48 hours at 37 °C and 5% carbon dioxide. Total RNA was isolated by using miRNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. The RNA yield and quality were determined with a NanoDrop ND1000 UV-vis Spectrophotometer (Thermo Fisher, Waltham, MA). For amplification of genes of interest, cDNA was transcribed with the High Capacity cDNA Reverse Transcript Amplification Kit (Applied Biosystems, Foster City, CA), according to the manufacturer’s instructions. The primers amplifying the genes of interest were designed by using the publicly accessible Primer-BLAST software (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Real-time PCR reactions were performed in 384-well plates with 10 ng cDNA per well plate using the Fast Start SYBR Green Master Mix (Roche Applied Science, Penzberg, Germany), and fluorescence was monitored with the ViiA7 Real-Time PCR machine (Applied Biosystems). The expression of transcripts was normalized to the expression of 18S ribosomal RNA as a housekeeping gene. Relative quantification was determined according to the following formula: relative quantification = 2‒ΔΔCt. Primers used were as follows: 18S forward 5′-GTAACCCGTTGAACCCCATT-3′; 18S reverse 5′-CCATCCAATCGGTAGTAGCG-3′; human β-defensin 2 forward 5′-AAGGTGGAAGGCTTGATGTCC-3′, reverse 5′- TACCACCAAAAACACCTGGAA-3′; Ki67 forward 5′-GCAAGCACTTTGGAGAGCAAAT-3′, reverse 5′-GTCCTCAGCCTTCTTTGGATT-3′. Cytokine levels from cell-culture supernatant were measured by sandwich ELISA for IL-6, TNF-α, and CCL17 using commercially available kits following the manufacturer’s instructions (IL-6 from Becton, Dickinson and Company; TNF-α and CCL17 from Research and Diagnostic Systems, Minneapolis, MN). Serum cytokine levels were measured with the Bio-Plex Pro Human Cytokine 27-plex Assay (Bio-Rad Laboratories, Hercules, CA), according to the manufacturer’s instructions. Heatmaps were generated using the R package pheatmap. Data were log transformed and scaled per cytokine. Statistical analysis was performed using GraphPad Prism 7.00 software (GraphPad Software, La Jolla, CA). Variables were correlated using Pearson rank correlation. Lines show the mean values with SEM. Box plots extend from 25th to 75th percentile with whiskers plotted to the minimum and maximum showing all data points. The line in the middle of the box is plotted at the median. Statistical differences were calculated by paired or unpaired t-tests and expressed as P-values: P ≥ 0.05 = not significant; ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.Supplementary Figure S2Selective IgE IA does not induce immune cell death nor reduces stimulatory capacity. (a) Differential blood cell count as a percentage in responders (left graphs) and non-responders (right graphs) at baseline (upper row) and follow-up (lower row). (b) Expression of activation marker CD63 on basophils (y-axis) upon stimulation with α-FcεRI in responders (red box plots) versus non-responders (blue box plots) over time (x-axis). (c) Representative dot plot of one responder (red, upper graphs) and one non-responder (blue, lower graphs) of BAT. (d) Percentage of living B cells (upper graph) and T cells (lower graph) in responders (red) and non-responders (blue) over time as observed by flow cytometry. (e) RNA expression of Ki67 in PBMCs of responders (upper graph) and non-responders (lower graph). Values are normalized to baseline and shown on a logarithmic scale (y-axis). BAT, basophil activation test; IA, immune apheresis; t, time.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Supplementary Figure S3Not FcεRIα levels but early and sustained downregulation of CD23 on B-cell populations predicts long-term response of selective IgE IA. (a) Gating strategy of peripheral immune cells. (b) Left graphs: FcεRIα levels on basophils (upper row), eosinophils (middle row), and monocytes (lower row) in responders (solid lines) and non-responders (dotted lines) over time. Middle and right graphs: Comparison of FcεRIα levels on basophils (upper graphs), eosinophils (middle graphs), and monocytes (lower graphs) in responders (red box plots) and non-responders (blue box plots) at baseline (middle left graphs), after last IA treatment (middle right graphs), and follow-up (right graphs). (c) Dot plots of CD23 levels of CD38highCD24− B cells in one representative responder (upper graphs) and one non-responder (lower graphs) over time (x-axis). (d) The course of CD23 levels on CD38highCD24− B cells (lines) and SCORAD (filled area) in responders (solid line, upper graph) and non-responders (dotted line, lower graph) over time (x-axis). (e) Mean CD23 levels of CD38highCD24− B cells in responders (red) and non-responders (blue) at follow-up. IA, immune apheresis; MFI, mean fluorescence intensity; NKT, NK T cell; SCORAD, scoring atopic dermatitis; SSC, side scatter; t, time.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Supplementary Figure S4Screening assay of 24 immune mediators in responders (red circles) and non-responders (blue squares) secreted by α-IgE stimulated B cells at follow-up. Y-axis shows the log transformed values.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Supplementary Table S1Patient CharacteristicsCharacteristicPt1Pt2Pt3Pt4Pt5Pt6Pt7Pt8Pt9Pt10Average ± SDSexMFMMMMFMMMOther atopic diseasesAR, FIAR, AAR, AAR, FIAR, FIAR, A, FIARAR, A, FIAR, A, FIAR, A, FIPrevious therapiesP, CS, IA + OMP, CSP, CS, IA + OMPT, CSP, CS, CYCP, MTX, CYC, OMP, CS, CYCP, CS, CYC, MTX, CCP, CSP, CS, CYCAge, y5245472836342339305338.7 ± 10.3Baseline SCORAD43.453.161.453.95047.151.74070.976,154.8 ± 11.6Follow-up SCORAD20.826.727.429.816.254.342.744.662Dropout36.1 ± 15.6Baseline IgE16,2114,91817,6574,7597,4872,32916,23219,79632,23628,69415,031.9 ± 10,226.1Follow-up IgE16,2063,83410,9294,7816,1803,28023,42423,25921,102Dropout12,555 ± 8,550.5Baseline DLQIAbsent716Absent12241218Absent1314.6 ± 5.4Follow-up DLQIAbsent210712119517Dropout10.3 ± 7.8Abbreviations: A, asthma; AR, allergic rhinitis; CC, Cellcept; CS, systemic corticosteroids; CYC, cyclosporin; DLQI, Dermatology Life Quality Index; F, female; FI, food intolerance; IA, immune apheresis; M, male; MTX, methotrexate; O, omalizumab; Pt, patient; P, phototherapy; SCORAD, scoring atopic dermatitis. Open table in a new tab Abbreviations: A, asthma; AR, allergic rhinitis; CC, Cellcept; CS, systemic corticosteroids; CYC, cyclosporin; DLQI, Dermatology Life Quality Index; F, female; FI, food intolerance; IA, immune apheresis; M, male; MTX, methotrexate; O, omalizumab; Pt, patient; P, phototherapy; SCORAD, scoring atopic dermatitis.

Abstract:Initiation of allergic airway pathology often depends on the protease activity of the inhaled allergen. Previous studies have shown that IL-17–driven neutrophil and eosinophil responses can promote allergic pathology1Kim J. Chang Y. Bae B. Sohn K.H. Cho S.H. Chung D.H. et al.Innate immune crosstalk in asthmatic airways: innate lymphoid cells coordinate polarization of lung macrophages.J Allergy Clin Immunol. 2019; 143: 1769-1782.e11Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar and are associated with an initial epithelial release of IL-23, which is accepted as important in promoting TH17 and group 3 innate lymphoid cell (ILC3) responses. ILC3s are a developmentally and phenotypically diverse innate lymphoid cell (ILC) subset that includes natural killer (NK) cell receptor (NCR)-positive and NCR-negative populations (NCR+ ILC3s and NCR– ILC3s) as well as CCR6+ lymphoid tissue inducer cells. However, all ILC3s are defined by expression of transcript variant 2 of RORC, encoding retinoid-related orphan receptor γt (RoRγt) and production of IL-17 and IL-22.1Kim J. Chang Y. Bae B. Sohn K.H. Cho S.H. Chung D.H. et al.Innate immune crosstalk in asthmatic airways: innate lymphoid cells coordinate polarization of lung macrophages.J Allergy Clin Immunol. 2019; 143: 1769-1782.e11Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar,2Ardain A. Domingo-Gonzalez R. Das S. Kazer S.W. Howard N.C. Singh A. et al.Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis.Nature. 2019; 570: 528-532Crossref PubMed Scopus (95) Google Scholar Work carried out in murine models has resulted in ILC3s emerging as critical regulators of infectious2Ardain A. Domingo-Gonzalez R. Das S. Kazer S.W. Howard N.C. Singh A. et al.Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis.Nature. 2019; 570: 528-532Crossref PubMed Scopus (95) Google Scholar and noninfectious1Kim J. Chang Y. Bae B. Sohn K.H. Cho S.H. Chung D.H. et al.Innate immune crosstalk in asthmatic airways: innate lymphoid cells coordinate polarization of lung macrophages.J Allergy Clin Immunol. 2019; 143: 1769-1782.e11Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar pulmonary diseases despite ILC3s representing only a minor lung immune cell population in mice. In contrast, ILC3s are the major ILC population in the human lung.3De Grove K.C. Provoost S. Verhamme F.M. Bracke K.R. Joos G.F. Maes T. et al.Characterization and quantification of innate lymphoid cell subsets in human lung.PLoS One. 2016; 11e0145961Crossref PubMed Scopus (96) Google Scholar Importantly, ILC3-associated preclinical phenotypes are reflective of observations in humans.2Ardain A. Domingo-Gonzalez R. Das S. Kazer S.W. Howard N.C. Singh A. et al.Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis.Nature. 2019; 570: 528-532Crossref PubMed Scopus (95) Google Scholar,4Jonckheere A.C. Bullens D.M.A. Seys S.F. Innate lymphoid cells in asthma: pathophysiological insights from murine models to human asthma phenotypes.Curr Opin Allergy Clin Immunol. 2019; 19: 53-60Crossref PubMed Scopus (21) Google Scholar However, our understanding of the molecular machinery enabling ILC3s to exact their influence on lung immunity is incomplete. In this study, we have demonstrated that expansion of lung ILC3s occurs in response to the protease papain and that these cells promote an IL-17–associated lung pathology. Critically, we have shown that induction of papain-driven pathology is strongly associated with ILC3 synthesis of acetylcholine (ACh). We have previously identified ACh responsiveness by immune cells in the lung as being important for CD4+ T-cell–driven adaptive immunity to Nippostrongylus brasiliensis infection.5Darby M. Schnoeller C. Vira A. Culley F.J. Bobat S. Logan E. et al.The M3 muscarinic receptor is required for optimal adaptive immunity to helminth and bacterial infection.PLoS Pathog. 2015; 11e1004636Crossref PubMed Scopus (30) Google Scholar Here, we have extended this insight by demonstrating that ACh from lineage-negative (Lin–) CD127+ lymphocytes expressing RoRγt is instrumental for promoting protease induction of allergic inflammation. This identifies a new paradigm for how ILC3s and ACh contribute to early promotion of allergic pathology that is distinct from our traditional understanding of ACh-driven neuromuscular interactions causing allergic pulmonary airway resistance. We have identified association of ILC3s with protease-induced lung pathology following acute papain challenge of wild-type (WT) C57BL/6 mice. Papain challenge increased lung concentrations of IL-13, IL-17A, IL-22, and IL-23 in comparison with the concentrations in saline-challenged mice (Fig 1, A). IL-17– and IL-23–promoted pathology suggests a RoRγt-driven inflammation. Papain challenge of RoRγt–green fluorescent protein (GFP) reporter mice demonstrated a significant expansion of the numbers of ILC3s (Lin–CD45+CD127+ICOS–RoRγt-GFP+), group 2 ILCs (ILC2s) (Lin–CD45+CD127+ICOS+RoRγt-GFP–), and CD3+CD4+ RoRγt-GFP+ T cells relative to the numbers in saline-treated controls (Fig 1, B and see Fig E1 in this article's Online Repository at www.jacionline.org). Restimulation and intracellular cytokine capture of lung CD4+ T cells from papain-challenged mice detected increased levels of IL-5 and IL-13 but not IL-17 when compared with the levels in saline-treated controls (Fig 1, C). However, in CD45+CD3–Lin– cells, in addition to increased levels of IL-5 and IL-13, a raised IL-17 level was detected in papain-challenged mice when compared with the levels in saline-treated controls (Fig 1, C). Moreover, anti-CD3 depletion of T cells did not protect against and in fact promoted papain-driven pathology (see Fig E2 in this article's Online Repository at www.jacionline.org). These findings support IL-17–driven pathology as being independent of RoRγt+ TH17 T-cell IL-17 production. To test a requirement for any T-cell (and B-cell) contribution to IL-23/IL-17–promoted pathology, we challenged RAG2–/– mice with papain in the presence or absence of an IL-23–neutralizing mAb (anti–IL-23) (Fig 1, D). Decreased lung inflammation in IL-23–depleted RAG2–/– mice was revealed by histologic analysis as well as by reduced detection of Evans blue (EB) leakage into bronchoalveolar lavage fluid (BALF) (Fig 1, D) when compared with that in isotype-treated RAG2–/– mice. BALF immune cell infiltration was reduced in all immune cell populations, and tissue levels of IL-17A (but not IL-13) were lower in the IL-23–depleted RAG2–/– mice (Fig 1, D). This abrogation of papain-induced allergic inflammation in anti–IL-23–treated RAG2–/– mice supports ILC3s as being a key contributing lymphoid cell population driving protease-mediated lung inflammation. To further characterize the input of ILC3s to allergic airway pathology, we compared pulmonary responses to papain in WT and Rorc–/– mice (Fig 1, E). Rorc–/– mice did not show significant baseline differences from C57Bl/6 mice in terms of BALF cell composition (see Fig E3 in this article's Online Repository at www.jacionline.org), but histologic analysis of lung sections revealed decreased inflammation and detection of EB leakage into the BALF in Rorc–/– mice challenged with papain versus in WT mice (Fig 1, E). Total BALF immune cell infiltration was also reduced for all immune cell populations (Fig 1, E). Moreover, detection of both IL-13 and IL-17A, as well as IL-22, was reduced in Rorc–/– mice (Fig 1, E). In agreement with findings by others6Lim A.I. Li Y. Lopez-Lastra S. Stadhouders R. Paul F. Casrouge A. et al.Systemic human ILC precursors provide a substrate for tissue ILC differentiation.Cell. 2017; 168: 1086-1100.e10Abstract Full Text Full Text PDF PubMed Scopus (299) Google Scholar Rorc–/– mice had expanded numbers of ILC2s (Lin–CD45+CD127+ICOS+) when compared with the numbers in WT mice (Fig 1, E). However, as expected, detection of ILC3 subsets such as NCR+ ILC3s (Lin–CD45+CD127+ICOS–NKp46+) in Rorc–/– mice was acutely reduced as opposed to in WT mice; the small number of cells detected were most likely to be non-NK, non–RoRγt-expressing group 1 ILCs (ILC1s). This body of work identifies a previously unappreciated, T-cell–independent role for IL-23–responsive ILC3s in contributing to the onset of papain-driven lung pathology. An additional striking feature of these results was protection from cholinergic-promoted airway resistance during papain challenge in the absence of Rorc expression (Fig 1, E). Lymphocytes are important responders to, and sources of, neurotransmitters. For example, the ILC2 response to the neurotransmitter neuromedin U is critical for inducing type 2 immunity,7Cardoso V. Chesne J. Ribeiro H. Garcia-Cassani B. Carvalho T. Bouchery T. et al.Neuronal regulation of type 2 innate lymphoid cells via neuromedin U.Nature. 2017; 549: 277-281Crossref PubMed Scopus (305) Google Scholar and production of ACh by immune cells following type 2 immune challenge can promote host type 2 immune responses.8Roberts L.B. The influence of non-neuronal cholinergic signalling on the type 2 immune response. Imperial College London, London, UK2017Google Scholar Moreover, ACh-producing T cells can contribute to control of chronic viral infection,9Cox M.A. Duncan G.S. Lin G.H.Y. Steinberg B.E. Yu L.X. Brenner D. et al.Choline acetyltransferase-expressing T cells are required to control chronic viral infection.Science. 2019; 363: 639-644Crossref PubMed Scopus (45) Google Scholar and CD4+ T-cell responses to ACh via the M3 muscarinic receptor are required for optimal adaptive immunity to helminth and bacterial infections.5Darby M. Schnoeller C. Vira A. Culley F.J. Bobat S. Logan E. et al.The M3 muscarinic receptor is required for optimal adaptive immunity to helminth and bacterial infection.PLoS Pathog. 2015; 11e1004636Crossref PubMed Scopus (30) Google Scholar In the spleen, lymphocytes are major effectors of the cholinergic anti-inflammatory pathway through their synthesis and release of ACh, which downregulates inflammation. ILC3 responses to cholinergic stimulation can also contribute to the cholinergic anti-inflammatory pathway by regulating neutrophilia in sepsis models. However, whether ILC3s themselves may be an immune cell–derived source of ACh capable of regulating immunity has not previously been investigated. To identify whether lung ILC3s may produce ACh during acute protease-induced inflammation, we challenged ChAT(BAC)-eGFP reporter mice with papain. In addition to increased choline acetyltransferase (ChAT) production by CD3+CD4+ cells (and a trend toward increased production by Lin–CD45+CD127+ICOS+ ILC2s), we identified an increase in the ChAT-expressing ILC3-enriched (Lin–CD45+CD127+ICOS–) population, but with no effect on the number of NK (CD3–DX5+) cells in the lungs of papain-challenged mice (Fig 2, A). Therefore, RoRγt-expressing ILC3s increase synthesis of ACh following papain challenge. To test whether ILC3 synthesis of ACh contributes to papain-driven pathology, we generated RoRγtCreChATloxp mice. These mice lack the ability to generate ACh following deletion of ChAT in RoRγt-expressing cells. Papain challenge of RoRγtCreChATloxp mice resulted in decreased histologic detection of inflammation and vascular leakage of EB in BALF compared with in the BALF of ChATloxp mice (Fig 2, B), along with reduced methacholine-induced airway resistance and reduced numbers of neutrophils and eosinophils in the BALF (Fig 2, B). Detection of cytokines in lung homogenates identified reduced IL-13 and IL-17A levels as well as reduced IL-22 levels, in RoRγtCreChATloxp mice as compared with in the controls (Fig 2, B). Therefore, disruption of ChAT in RoRγt+ cells was sufficient to recapitulate the reduced pathology seen in papain-challenged Rorc–/– mice (Fig 1). Quantification of ILCs revealed equivalent ILC2 (Lin–CD45+CD127+ICOS+) numbers but decreased NCR+ ILC3 (Lin–CD45+CD127+ICOS–NKp46+) numbers between papain-challenged WT and RoRγtCreChATloxp mice (Fig 2, B). An equivalent phenotype was demonstrated following Alternaria alternata extract–driven acute allergic inflammation (Fig 2, C). As with papain, A alternata extract challenge of RoRγtCreChATloxp mice resulted in decreased histologic detection of inflammation and vascular leakage of EB in BALF along with reduced methacholine-induced airway resistance, reduced numbers of neutrophils and eosinophils in the BALF, and reduced detection of IL-13 and IL-17A in lung homogenates compared with in ChATloxp mice (Fig 2, C). In summary, following acute protease challenge, we found raised IL-13, IL-23, IL-22, and IL-17A expression in the lung and increased numbers of ILC3s. Papain challenge did not induce elevated CD4+ T-cell IL-17 levels irrespective of raised RoRγt+CD4+ T-cell numbers. Moreover, in the absence of T cells, papain-induced lung inflammation was maintained but abrogated when IL-23 or RoRγt function was disrupted. This strongly supports ILC3 expansion in the lung as a driving factor in IL-17–associated inflammation following an acute protease lung challenge. Reduction in airway cholinergic responsiveness led us to investigate whether ILC3s were a physiologically relevant source of ACh following papain challenge. We tested this by generating RoRγtCreChATloxp mice that lack the ability to generate ACh in RoRγt-expressing cells. Remarkably, this ILC3-biased disruption of ChAT expression protected against pathology to an extent equivalent to that seen in Rorc–/– mice. This identifies RoRγt+ cell expression of ChAT as an important component in the promotion of protease-mediated allergic lung pathology. Indeed, these data support ILC3s expressing ACh as playing a central role in initiation of the IL-17–promoted allergic inflammatory cascade. These findings place ILC3 synthesis of ACh as a central requirement for allergic lung inflammation, adding a critical new paradigm to our understanding of cholinergic responses in driving allergic lung inflammation and pathology. We would like to acknowledge Elodie Culerier for her technical assistance and Marc Le Bert (INEM UMR7355 Experimental and Molecular Immunology and Neurogenetics, CNRS and University of Orleans) for expert advice on mouse genetics. All mice used in this study were 6- to 12-week-old C57BL/6 background mice. The mouse strains used were C57BL/6, RAG2–/–, ChAT(BAC)-eGFP,E1Tallini Y.N. Shui B. Greene K.S. Deng K.Y. Doran R. Fisher P.J. et al.BAC transgenic mice express enhanced green fluorescent protein in central and peripheral cholinergic neurons.Physiol Genomics. 2006; 27: 391-397Crossref PubMed Scopus (129) Google Scholar RoRγt-eGFP,E2Eberl G. Marmon S. Sunshine M.J. Rennert PD, Choi Y, Littman DR. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells.Nat Immunol. 2004; 5: 64-73Crossref PubMed Scopus (778) Google Scholar RoRγt-KO (Rorc–/–),E3Sun Z. Unutmaz D. Zou Y.R. Sunshine M.J. Pierani A. Brenner-Morton S. et al.Requirement for RORgamma in thymocyte survival and lymphoid organ development.Science. 2000; 288: 2369-2373Crossref PubMed Scopus (588) Google Scholar, E4Eberl G. Littman D.R. Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells.Science. 2004; 305: 248-251Crossref PubMed Scopus (402) Google Scholar RoRγtCre,E3Sun Z. Unutmaz D. Zou Y.R. Sunshine M.J. Pierani A. Brenner-Morton S. et al.Requirement for RORgamma in thymocyte survival and lymphoid organ development.Science. 2000; 288: 2369-2373Crossref PubMed Scopus (588) Google Scholar and ChATloxp.E5Misgeld T. Burgess R.W. Lewis R.M. Cunningham J.M. Lichtman J.W. Sanes J.R. Roles of neurotransmitter in synapse formation: development of neuromuscular junctions lacking choline acetyltransferase.Neuron. 2002; 36: 635-648Abstract Full Text Full Text PDF PubMed Scopus (248) Google Scholar Rorc–/– mice are deficient in expression of transcript variant 2 of RORC, encoding RoRγt. RoRγt is necessary for the development of lymph nodes and Peyer patches, which fail to develop in Rorc–/– mice.E4Eberl G. Littman D.R. Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells.Science. 2004; 305: 248-251Crossref PubMed Scopus (402) Google Scholar RoRγt is expressed by many cells, including immature double-positive (CD4+CD8+) αβ thymocytes, RoRγt+ TH17 T cells, and ILC3s, which comprise NCR+ ILC3s and NCR– ILC3s, as well as CCR6+ lymphoid tissue inducer cells. RoRγtCre and ChATloxp mice were crossed over 5 generations to generate RoRγtCreChATfl mice. The ChAT(BAC)-eGFP mouse has been demonstrated to faithfully report ChAT expression and ACh synthesis capacity across a number of hematopoietic immune cell types.E1Tallini Y.N. Shui B. Greene K.S. Deng K.Y. Doran R. Fisher P.J. et al.BAC transgenic mice express enhanced green fluorescent protein in central and peripheral cholinergic neurons.Physiol Genomics. 2006; 27: 391-397Crossref PubMed Scopus (129) Google Scholar As the major rate-limiting enzyme of crucial significance for ACh synthesis, demonstration of ChAT expression by a specific cell type is widely considered to reflect the cholinergic-synthesizing nature of the cell. The mice were anesthetized by isoflurane followed by intranasal administration of 25 μg of papain (Calbiochem, Darmstadt, Germany) in 40 μL of saline solution per mouse once per day on days 1, 2, and 3. On day 4 mice, were humanely killed by CO2 inhalation 24 hours after the final administration of papain. A alternata extract was administered daily for 3 days at a dose of 25 μg per mouse by the endotracheal route under light isoflurane anaesthesia, before the mice were humanely killed on day 4 by CO2 inhalation. Anti–IL-23 antibody or isotype control (Bio X cell, Lebanon, NH; BR0313 or rat IgG1) was given daily 1 hour before papain challenge at a dose of 200 μg per mouse via the endotracheal route. Anti-CD3 (Biolegend, San Diego, Calif; catalog no. BL100208) antibody or isotype controls was given via intraperitoneal injection daily 1 hour before papain challenge at a rate of 50 μg per mouse. After the mice were humanely killed, BALF was collected before cardiac perfusion with ISOTON II (acid-free balanced electrolyte solution, Beckman Coulter, Krefeld, Germany), after which the lungs were collected and sampled for analyses. All of the animal experimental protocols complied with French ethical and animal experiments regulations (see Charte Nationale, Code Rural R 214-122, 214-124 and European Union Directive 86/609/EEC) and were approved by the Ethics Committee for Animal Experimentation of CNRS Campus Orleans, registered (No. 3) by the French National Committee of Ethical Reflexion for Animal Experimentation (CLE CNRS Campus Orleans 2013-1006). All of the South African experiments were carried out in accordance with South African Veterinary Council regulations and were approved by the University of Cape Town Faculty of Health Sciences Animal Ethics Committee. The left lobe of lung was fixed in 4% buffered formaldehyde and paraffin embedded under standard conditions. Tissue sections (3-μm) were stained with standard hematoxylin and eosin and periodic acid–Schiff. The histologic score of the pathology was determined by a semiquantitative assessment on a scale of 0 to 5 for cell infiltration (with increasing extent). The slides were blindly examined by 2 investigators with a Leica microscope (Leica, Solms, Germany). Bronchoalveolar lavage was performed by 4 lavages of lung with 500 μL of saline solution via a cannula introduced into the mouse trachea. BALF samples were centrifuged at 400 g for 10 minutes at 4°C, the supernatants were stored at –20°C for analysis, and pellets were recovered to prepare Cytospin (Thermo Scientific, Waltham, Mass) on glass slides followed by staining with Diff-Quik stain (Merz & Dade AG, Dudingen, Switzerland). Differential cell counts were performed with at least 300 cells. Vascular leakage was quantified by protein and EB concentration in the BALF. EB in BALF was measured 45 minutes after intravenous injection of 0.3% EB; the measurement was performed by absorbance at 460 nm, as described elsewhere.E6Michaudel C. Mackowiak C. Maillet I. Fauconnier L. Akdis C.A. Sokolowska M. et al.Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL-33.J Allergy Clin Immunol. 2018; 142: 942-958Abstract Full Text Full Text PDF PubMed Scopus (63) Google Scholar Extravasation was expressed as micrograms of EB per milliliter (μg of EB/mL) of BALF supernatant. Lungs were digested in RPMI 1640 medium containing 100 U/mL of penicillin, 100 U/mL of streptomycin, 1 mg/mL of DNase I (Sigma, St Louis, Mo), and 125 μg of liberase (Roche, Basel, Switzerland) for 1 hour at 37°C under rotation. After digestion, RPMI 1640 medium supplemented with 10% FCS was added. Cells were dissociated by passage through a 70-μm cell strainer and centrifuged at 400 g for 5 minutes at 4°C. Pellets were resuspended in red blood cell lysis buffer (Stem Cell Technologies, Vancouver, British Columbia, Canada) and incubated for 10 minutes on ice. Lysis was stopped by addition of RPMI 1640 medium and centrifuged again at 400 g for 5 minutes at 4°C. Pellets were resuspended in RPMI 1640 medium supplemented with 10% FCS and passed through a 40-μm cell strainer. ILC2s were identified by using a Lin cocktail, CD45, CD127, and ICOS panel. ILC3s were identified by using a panel containing a Lin cocktail, CD45, CD127, ICOS, and NKp46 or RoRγt, as indicated. Cytokine-expressing T cells were identified by using a panel containing CD3, CD4, IL-5, IL-13, or IL-17, as indicated. NK cells were identified by using a panel containing CD3 and DX5. All FACS antibodies were from Biolegend. Homogenized lungs were tested for IL-13 and IL-17 by using commercial ELISA kits (eBiosciences, San Diego, Calif) according to the manufacturer's instructions. For invasive measurement of dynamic resistance, mice were anesthetized by intraperitoneal injection of solution containing ketamine (100 mg/kg, Merial, Duluth, Ga) and xylazine (10 mg/kg, Bayer, Leverkusen, Germany), paralyzed by using D-tubocuranine (0.125%, Sigma), and intubated with an 18-gauge catheter. Respiratory frequency was set at 140 breaths per minute with a tidal volume of 0.2 mL and a positive end-expiratory pressure of 2 mL of H2O. Increasing concentrations of aerosolized methacholine (9.375, 18.75, 37.5, 75, and 150 mg/mL) were administered. Resistance was recorded by using an invasive plethysmograph (Buxco, London, United Kingdom). Baseline resistance was restored before administration of the subsequent doses of methacholine.E7Madouri F. Chenuet P. Beuraud C. Fauconnier L. Marchiol T. Rouxel N. et al.Protein kinase Ctheta controls type 2 innate lymphoid cell and TH2 responses to house dust mite allergen.J Allergy Clin Immunol. 2017; 139: 1650-1666Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar Data were analyzed by using Prism software, version 5 or 6 (GraphPad Software, San Diego, Calif). Either a Mann-Whitney t test or the parametric 1-way ANOVA test with Bonferroni multiple-comparison was used to assess significance. Values are expressed as means ± SDs.Fig E2CD3-depleted ChAT-GFP mice do not show reduced inflammation to papain. Mice were treated daily with anti-CD3 antibody administered intraperitoneally 1 hour before papain challenge at a dose of 50 μg/mouse. BALF cellular infiltration was assessed 24 hours after final administration of papain. BAL, Bronchoalveolar lavage fluid; Eos., eosinophil; Gra., granulocyte; Lymp, lymphocyte; Mono., monocyte.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig E3Rorc–/– mice do not show significant baseline differences from C57Bl/6 mice in terms of BALF cell composition. BALF immune cell infiltration and levels of lung ILC2s (Lin–CD45+CD127+ICOS+) and NCR+ ILC3s (Lin–CD45+CD127+ICOS–NKp46+) in saline-treated C57Bl/6 and Rorc–/– mice were analyzed by flow cytometry. BAL, Bronchoalveolar lavage fluid; Eos., eosinophil; Gra., granulocyte; Lymp, lymphocyte; Mono., monocyte.View Large Image Figure ViewerDownload Hi-res image Download (PPT)

ILC2s and Basophils Team Up to Orchestrate IL-33–Induced Atopic Dermatitis

Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice

CD23 Levels on B Cells Determine Long-Term Therapeutic Response in Patients with Atopic Eczema Treated with Selective IgE Immune Apheresis.

Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human

ILC3-derived Acetylcholine Promotes Protease-Driven Allergic Lung Pathology

Experimental Atopic Dermatitis Depends on IL-33R Signaling Via MyD88 in Dendritic Cells

A novel function of NLRP3 independent of inflammasome as a key transcription factor of IL-33 in epithelial cells of atopic dermatitis

IL-37 Targets TSLP-Primed Basophils to Alleviate Atopic Dermatitis

Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis

IL-9 sensitizes human Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis

IL-3 produced by T cells is crucial for basophil extravasation in hapten-induced allergic contact dermatitis

Exaggerated IL-17 Response to Epicutaneous Sensitization Mediates Airway Inflammation in the Absence of IL-4 and IL-13.

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

IL-26 Potentiates Type 2 Skin Inflammation in the Presence of IL-1β

Insights into Intrinsic Atopic Dermatitis: immunogenicity, Dysbiosis, and Imaging (Reflectance Confocal Microscopy, Optical Coherence Tomography)

IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization.

Type 2 Innate Lymphoid Cells and Skin Fibrosis in a Murine Model of Atopic Dermatitis-Like Skin Inflammation

Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis

Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis

IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis

IL-6 influences the balance between M1 and M2 macrophages in a mouse model of irritant contact dermatitis